1. Introduction {#sec1-ijerph-15-01006}
===============

The Hebei Spirit oil spill (HSOS) occurred in the western coastal area of the Korean peninsula on 7 December 2007 \[[@B1-ijerph-15-01006]\], and was the worst of its kind in Korean waters \[[@B1-ijerph-15-01006]\]. In Taean, an oil band covered the coast that is very close to a residential area for one month \[[@B2-ijerph-15-01006]\]. Taean residents, in addition to over one million volunteers, and military and marine officers performed clean-up work for seven or eight months \[[@B2-ijerph-15-01006],[@B3-ijerph-15-01006]\]. However, in the first few days after the oil spill, clean-up workers were not appropriately protected \[[@B3-ijerph-15-01006]\].

The spilled oil contained volatile organic compounds (VOCs), polycyclic aromatic hydrocarbons (PAHs), and heavy metals \[[@B1-ijerph-15-01006]\]. Crude oil VOCs include benzene, toluene, ethylbenzene, and xylene (BTEX), which are group 1 or 2 human carcinogens according to the International Agency for Research on Cancer (IARC) \[[@B4-ijerph-15-01006]\]. PAHs are easily absorbed by the respiratory tract and cause damage to the red blood cells \[[@B1-ijerph-15-01006]\]. The IARC has classified some PAHs, such as bezo\[*a*\]pyrene, as group 1 human carcinogens, and benz\[*a*\]anthracene, dibenz\[*a,h*\]anthracene, chrysene, naphthalene, bezo\[*b*\]fluoranthene, bezo\[*k*\]fluoranthene, and indeno\[1,2,3-*cd*\]pyrene as group 2 human carcinogens \[[@B4-ijerph-15-01006],[@B5-ijerph-15-01006]\].

The HSOS continues to affect Taean County residents and clean-up workers, with the effects manifesting as various adverse health events across Korea, including acute-stage physical \[[@B3-ijerph-15-01006],[@B5-ijerph-15-01006],[@B6-ijerph-15-01006],[@B7-ijerph-15-01006],[@B8-ijerph-15-01006],[@B9-ijerph-15-01006]\] and mental health problems \[[@B2-ijerph-15-01006],[@B10-ijerph-15-01006],[@B11-ijerph-15-01006],[@B12-ijerph-15-01006]\] as well as mid- and long-term health problems \[[@B13-ijerph-15-01006],[@B14-ijerph-15-01006]\]. In a study conducted 1.5 years \[[@B13-ijerph-15-01006]\] after the spill, the oxidative DNA stress marker levels, which could be indicative of cancer risk, were higher in the high-exposure group than in the low-exposure group; the effect persisted for 6 years after the spill \[[@B14-ijerph-15-01006]\]. Chromosome damage was observed among fishermen in studies conducted two and six years after the Prestige oil spill in Spain \[[@B15-ijerph-15-01006],[@B16-ijerph-15-01006],[@B17-ijerph-15-01006]\], and cancer risk modeling was performed after the British Petroleum Deepwater Horizon (BPDH) oil spill in the United States of America (USA) \[[@B18-ijerph-15-01006]\].

While oil spills have occurred across the world, studies on the associated mid- and long-term health effects have been reported only in three countries: Spain (Prestige oil spill), the USA (Exxon Valdez oil spill \[[@B19-ijerph-15-01006],[@B20-ijerph-15-01006],[@B21-ijerph-15-01006]\] and the BPDH oil spill \[[@B18-ijerph-15-01006],[@B22-ijerph-15-01006],[@B23-ijerph-15-01006],[@B24-ijerph-15-01006],[@B25-ijerph-15-01006],[@B26-ijerph-15-01006],[@B27-ijerph-15-01006],[@B28-ijerph-15-01006],[@B29-ijerph-15-01006],[@B30-ijerph-15-01006],[@B31-ijerph-15-01006],[@B32-ijerph-15-01006],[@B33-ijerph-15-01006]\]), and Korea (HSOS) \[[@B2-ijerph-15-01006],[@B3-ijerph-15-01006],[@B5-ijerph-15-01006],[@B6-ijerph-15-01006],[@B7-ijerph-15-01006],[@B8-ijerph-15-01006],[@B9-ijerph-15-01006],[@B10-ijerph-15-01006],[@B11-ijerph-15-01006],[@B12-ijerph-15-01006],[@B13-ijerph-15-01006],[@B14-ijerph-15-01006]\]. There have been concerns pertaining to the potential development of cancers in the affected areas; however, few studies have focused on the cancer incidence among residents after the oil spill despite their consequent exposure to carcinogenic substances. These findings suggest the need for longitudinal studies on the cancer incidence in the affected areas. In this study, the authors aimed to assess the cancer incidence rate in the area affected by the HSOS and to compare it with that observed in other areas, before and after the oil spill.

2. Materials and Methods {#sec2-ijerph-15-01006}
========================

2.1. Study Areas {#sec2dot1-ijerph-15-01006}
----------------

### 2.1.1. Exposure Area {#sec2dot1dot1-ijerph-15-01006}

Taean County---the site of the HSOS---has eight towns, and we classified them into two areas of exposure ([Figure 1](#ijerph-15-01006-f001){ref-type="fig"}). Four towns (Sowon, Wonbuk, Geunheung, and Iwon) which face the oil-contaminated coast and are located at a distance of less than 15 km from the contaminated shore line were classified as high-exposure areas. The low-exposure areas comprised the remaining four towns (Taean-eup, Anmyeon, Gonam, and Nam), which include both inland (Taean-eup) and coastal areas; the distance to the contaminated shore line is 10 to 45 km. Further details have been described in previous studies \[[@B2-ijerph-15-01006],[@B34-ijerph-15-01006]\]. The mid-year population sizes (proportion of elderly adults) in 2007 were 9826 (21.3%) and 21,844 (13.2%) among men, and 9691 (30.4%) and 21,681 (19.7%) among women, in the high-exposure and low-exposure areas, respectively.

### 2.1.2. Comparison Areas {#sec2dot1dot2-ijerph-15-01006}

The observed cancer incidence rate and trend were compared with those observed nationwide and in similar coastal areas. We selected three coastal areas which had a population size that was similar to that of Taean County, with similar regional characteristics \[[@B37-ijerph-15-01006]\]. Area "a" is located in the same province and the same coastal area, area "b" in the neighboring province and the same coastal area, and area "c" in a different province and on a different coast ([Figure 1](#ijerph-15-01006-f001){ref-type="fig"}). The mid-year population sizes (proportion of elderly) in 2007 were 49,130,354 (10.2%), 63,398 (19.7%), 61,899 (25.1%), 62,561 (23.7%), and 79,829 (30.8%) in Korea, Taean County, area "a", area "b", and area "c", respectively.

2.2. Age-Standardized Cancer Incidence {#sec2dot2-ijerph-15-01006}
--------------------------------------

Five major cancers and leukemia (C91−C95) were selected for analysis. The five major cancers for Korean men are those of the stomach (C16), lung (C33−C34), colon (C18−C20), liver (C22), and prostate (C61); and those for Korean women are thyroid (C73), breast (C50), colon (C18−C20), stomach (C16), and lung (C33−C34) cancers \[[@B38-ijerph-15-01006]\]. Data on the cancer cases in each area by age group and sex, from 1999 to 2014, were obtained from the Division of Cancer Registration & Surveillance in the Korean National Cancer Control Institute \[[@B39-ijerph-15-01006]\].

The age-standardized incidence rate (SIR) was calculated using the mid-year Korean registration population in 2000 as the standard population. This method uses the same formula for the regional cancer incidence rate as that used in the Korean Statistical Information Service (KOSIS) \[[@B40-ijerph-15-01006]\]. Data on the regional population in Taean, Korea as a whole, and the coastal areas were obtained from the KOSIS during the study period \[[@B40-ijerph-15-01006]\].

2.3. Statistical Analysis {#sec2dot3-ijerph-15-01006}
-------------------------

To compare the SIRs between Taean or the HSOS-exposure areas in Taean and Korea as a whole or the coastal areas, the five- or six-year incidence rates and incidence rate ratios (IRRs) were calculated for 1999−2003, 2004−2008, and 2009−2014. To obtain the 95% confidence interval (CI), the standard error (SE) for the five-year or six-year incidence rate was calculated using a formula proposed by Boyle and Parkin \[[@B41-ijerph-15-01006]\]. Additionally, to compare the SIR trends among the areas, the SIRs were calculated per year. For the analyses, the SIR and SE were replaced by 0.0001 when the SIR was 0. The SE for the trend analyses was calculated using the joinpoint regression model formula \[[@B42-ijerph-15-01006]\].

To examine the cancer incidence trend in the areas, joinpoint regression analysis was performed. A model selection and average annual percent change (AAPC) comparison test were performed using the Monte Carlo permutation method \[[@B42-ijerph-15-01006]\] through the Joinpoint Regression Program version 4.5.0.1 (Bethesda, MD, USA) \[[@B43-ijerph-15-01006]\]. Average annual percent change (APC) during the period means that the increase in the cancer incidence rate is equivalent during the period. In the final model, each joinpoint indicates a significant change in the slope and a zero joinpoint implies the absence of a significant change in the slope, that is, the AAPC is the same as the APC \[[@B42-ijerph-15-01006]\]. A permutation test that estimates the optimal number of joinpoints was applied after all the analyses, at a significance level of 0.05 \[[@B43-ijerph-15-01006]\].

2.4. Ethics Statement {#sec2dot4-ijerph-15-01006}
---------------------

This study was approved by the Institutional Review Board of Dankook University Hospital, Cheonan, Korea (DKUH 2015-12-012; DKUH 2017-03-032). According to the Privacy Protect Act in Korea, informed consent is not required for the use of anonymized national statistics datasets.

3. Results {#sec3-ijerph-15-01006}
==========

3.1. Age-Standardized Incidence Rate and Incidence Rate Ratio {#sec3dot1-ijerph-15-01006}
-------------------------------------------------------------

[Table 1](#ijerph-15-01006-t001){ref-type="table"} presents the five (or six)-year cancer incidence rate and SIR ratio of five major cancers in Taean and the exposed areas (vs. nationwide and in the coastal areas), from 1999 to 2014. In men, the SIRs of prostate cancer in Taean and the high-exposure areas were significantly higher than those in the coastal areas, from 2009 to 2014 (IRR (95% CI), Taean vs. coastal areas = 1.2 (1.01, 1.53); high-exposure area vs. coastal areas = 1.4 (1.01, 1.92)). The SIRs in Taean and the high-exposure areas were higher than those observed nationwide, but this was not significant. In women, the SIRs for leukemia in Taean and the high-exposure areas were higher than those in the other areas, from 2009 to 2014, but this was not significant.

3.2. Trend of Cancer Incidence (Taean vs. Nationwide) {#sec3dot2-ijerph-15-01006}
-----------------------------------------------------

[Figure 2](#ijerph-15-01006-f002){ref-type="fig"} shows the cancer incidence trend in Taean and Korea as a whole from 1999 to 2014. The SIRs of all cancers excluding thyroid cancer showed an increased annual average of 0.6% (95% CI: −0.3, 1.5), 0.1% (95% CI: −0.3, 0.4), 1.4% (95% CI: 0.3, 2.5), and 1.5% (95% CI: 1.1, 1.8), in Taean men, men nationwide, Taean women, and women nationwide, respectively. The SIRs of prostate cancer in men increased at an annual average of 8.1% (95% CI: −4.1, 21.8) in Taean and 8.8% (95% CI: 7.5, 10.1) nationwide, while those of leukemia in women increased at an annual average of 9.5% (95% CI: −26.6, 63.4) in Taean and 0.6% (95% CI: 0.2, 0.9) nationwide. In terms of prostate cancer, from 2007 to 2009 the SIRs increased at an annual average of 39.3% in Taean and 13.5% nationwide, but this was not significant. When the AAPCs of Taean and Korea were compared, the trends were not significantly different except in the case of thyroid and prostate cancer, and leukemia in women.

3.3. Trend of Cancer Incidence (Taean vs. the Coastal Areas) {#sec3dot3-ijerph-15-01006}
------------------------------------------------------------

[Figure 3](#ijerph-15-01006-f003){ref-type="fig"} illustrates the cancer incidence trend in Taean and the coastal areas from 1999 to 2014. The SIRs of all cancers excluding thyroid cancer in the coastal areas increased at an annual average of 0.4% (95% CI: −0.1, 0.9) in men and 2.0% (95% CI: 0.9, 3.0) in women. The SIRs of prostate cancer increased at an annual average of 8.1% (95% CI: −4.1, 21.8) in Taean and 10.8% (95% CI: 8.0, 13.7) in coastal areas, while those of leukemia among women increased at an annual average of 9.5% (95% CI: −26.6, 63.4) in Taean. However, a decrease of 1.9% (95% CI: −12.8, 10.4) was observed in the coastal areas. In terms of prostate cancer, from 2007 to 2009 the SIRs increased at an annual average of 39.3% (95% CI: −25.9, 161.8) in Taean and 15.6% (95% CI: 11.9, 19.5) in the coastal areas. When the AAPCs of Taean and the coastal areas were compared, the trends were significantly different in terms of prostate cancer (*p* = 0.0004) but not in all cancers, excluding thyroid cancer and leukemia among women.

4. Discussion {#sec4-ijerph-15-01006}
=============

In this study, we found that the incidence rate of prostate cancer has increased in Taean since 2007 and is higher than that observed in other coastal areas, in 2009−2014. Furthermore, the incidence rates were higher in the high-exposure areas than in the low-exposure areas. Additionally, the APC of the incidence rates in Taean was higher than that observed nationwide and in the coastal areas (Taean \[2007--2010\]: 39.3%; nationwide \[1999--2009\]: 13.5%; coastal areas \[1999--2009\]: 15.6%). However, as cancer can develop as late as 10 years after exposure, it may be difficult to conclude that the cancer developed because of exposure to the oil spill.

In Taean, a coal-fired power plant has been in existence since 1995 \[[@B44-ijerph-15-01006]\]; it is located on the same coast 15 km away from the spot of the oil spill \[[@B35-ijerph-15-01006]\]. The high-exposure HSOS areas largely overlap with the areas with high exposure to compounds from the power plant. Therefore, it could be assumed that residents previously exposed to the coal power plant may have been exposed to the oil spill too; the interaction between these environmental exposures should be taken into account.

In Korea, the prostate cancer incidence rate has increased since 1999 when the cancer database was set up \[[@B45-ijerph-15-01006]\]. According to the Korean National Cancer Control Institute in the National Cancer Center, the prevalence of prostate cancer has increased and the disease is highly prevalent in areas with a high social economic status (SES); additionally, a high screening rate for prostate cancer leads to detection bias \[[@B46-ijerph-15-01006]\]. A previous study reported that men with a low educational level have a low risk for prostate cancer \[[@B47-ijerph-15-01006]\]. The incidence rate of prostate cancer was higher among firefighters, as observed in a meta-analysis, due to exposure to VOCs and PAHs \[[@B48-ijerph-15-01006]\].

In Taean, especially in the high-exposure areas, residents have a low SES \[[@B49-ijerph-15-01006]\] and the medical facilities are poor and scarce: the numbers of medical doctors in medical institutes per 1000 of the population were 1.25 in 2007 and 1.5 in 2014, in Taean \[[@B40-ijerph-15-01006]\], while the corresponding values nationwide were 1.9 in 2007 and 2.23 in 2014 \[[@B50-ijerph-15-01006]\]. Additionally, the Korean National Cancer Screening Program includes only the stomach, liver, colon, breast, and cervix, and the overall rate of participation was 36.3% in 2013 \[[@B38-ijerph-15-01006]\]. Therefore, there is no obvious evidence of detection bias for the increasing incidence of prostate cancer.

We found that the incidence of leukemia among female Taean residents had increased and was higher than in the other coastal areas and nationwide, in 2009−2014. The incidence rates were higher in the high-exposure areas than the low-exposure areas. However, the IRR was not significantly high because leukemia is not a common disease and also due to the fact that Taean has a small population. Conversely, in men, the leukemia incidence rate decreased in Taean and was lower in the high-exposure areas than the low-exposure areas in 2009−2014. Additionally, the incidence rate (/100,000) was higher among women (7.3) than men (4.7) in 2009--2014 in Taean, but was higher among men than women in the coastal areas, at 5.8, 4.1, 4.9, and 3.9, among Korean men, Korean women, men in coastal areas, and women in coastal areas, respectively ([Supplementary Table S1](#app1-ijerph-15-01006){ref-type="app"}). In this study, the leukemia incidence rate among women, especially those living in high-exposure areas, increased, while that of men decreased. That could be because the incidence rate of leukemia among women younger than 20 years living in high-exposure areas was higher in 2009−2014 (case = 3) than in 2004−2008 (case = 0); the incidence rate of the disease in men was lower in 2009−2014 (case = 0) than in 2004−2008 (case = 1). A previous study reported that hematologic malignancies are generally more commonly observed in men; while this can be generalized to most other cancers worldwide, infant leukemia could be an exception \[[@B51-ijerph-15-01006]\]. Nevertheless, the latency period of leukemia after hazard exposure is less than 5 years \[[@B52-ijerph-15-01006]\]. One study reported that the risk of developing leukemia was higher among those living near oil and gas exploitation areas compared to those living far away from such areas \[[@B53-ijerph-15-01006]\]. Additionally, organic solvents including benzene are well-known to be risk factors for leukemia \[[@B54-ijerph-15-01006]\]. Our study has some limitations associated with its small sample size and low observed incidence rate. Studies with a longer follow-up are needed to examine the leukemia incidence trend, along with additional analyses for all hematopoietic cancers including leukemia, the latency time of which is within 5 years after exposure.

In this study, we selected comparison areas that are similar to Taean in terms of their characteristics, such as the predominance of the farming, fishing, and tourism industries \[[@B37-ijerph-15-01006],[@B55-ijerph-15-01006]\], and also the population sizes and proportion of elderly adults (in [Figure 1](#ijerph-15-01006-f001){ref-type="fig"}). Cancer incidence rates vary between cities and rural areas \[[@B56-ijerph-15-01006]\]. In addition, even in terms of rural areas, the SES level and dietary culture may vary between inland and coastal regions, as well as suburban areas and farming/fishing villages.

In this study, when we compared the cancer incidence rate, excluding that of thyroid cancer, between Taean and Korea as a whole, we found that the incidence rate tended to increase in Taean during all the periods, but not nationwide, since 2011. We excluded thyroid cancer from the analysis because of the potential detection bias associated with thyroid cancer in Korea. Enhanced accessibility to low-cost diagnostic procedures is reported to have increased the incidence of thyroid cancers with carcinomas smaller than 1 cm in size in Korea \[[@B57-ijerph-15-01006]\].

We could not investigate the obvious association between oil exposure and cancer incidence in this study. Although we could not identify the reason for the rapid increase in the incidence rate, we found that the incidence rate of prostate cancer was higher among Taean residents than those living in the other coastal areas; the incidence rates were higher in the high-exposure areas, especially after the HSOS. Additionally, we could not prove the aforementioned association because ours is an ecological study. However, our study participants were all Taean residents, and the reliability and validity of our data are high as we used national data. We did not adjust for confounding factors, such as smoking habit, alcohol consumption, exercise status, SES, health status, and family history, or consider exposure factors, such as the duration of clean-up work and frequency of visits to the oil spill site except for the exposure in the living area. Our study period was not long enough for the cancer incidence after exposure to be analyzed. Therefore, studies with a longer follow-up period are needed. Advanced analyses such as age-period-cohort analyses may provide additional clues pertaining to oil spill exposure and cancer development. Despite these limitations, however, this is the first long-term follow-up study to examine the cancer incidence trend according to oil spill exposure using a national cancer registry of all residents exposed to the oil spill.

The incidence rate of prostate cancer and burden of the disease have been increasing in Korea \[[@B45-ijerph-15-01006]\] and worldwide \[[@B58-ijerph-15-01006]\]. This can be investigated through advanced research focusing on the birth cohort effect or role of carcinogens. However, although it is important to clarify the reason for the increase in the cancer incidence rate, it is necessary to conduct screening for early detection and provide treatment for residents.

5. Conclusions {#sec5-ijerph-15-01006}
==============

After the HSOS, an increased incidence rate of cancer was observed among Taean residents, particularly in terms of prostate cancer. Studies with a longer follow-up are needed to accurately identify the association between cancer incidence and oil spill in residents.

This study was supported by a Taean Environmental Health Center operating grant for the Investigation of Long-term Health Effects of the Hebei Spirit Oil Spill, Ministry of Environment, Republic of Korea.

The following are available online at <http://www.mdpi.com/1660-4601/15/5/1006/s1>, Table S1: Age-standardized incidence rate of five major cancer in Korea and coastal areas, 1999-2014.
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![Map of Taean County and comparison of the coastal areas (a, b, and c) in Korea. (**A**) Comparison areas, "a": Same province and same coastal area, "b": Neighboring province and same coastal area, and "c": Different province and different coast. The areas for comparison were selected based on their similarities to Taean County in terms of their characteristics and population size. (**B**) Taean County according to exposure level. I: Sowon, II: Wonbuk, III: Iwon, IV: Geunheung, V: Taean-eup, VI: Nam, VII: Anmyeon, and VIII: Gonam. The maps were drawn using Google maps (2018) \[[@B35-ijerph-15-01006]\] and ggplot2 in R package \[[@B36-ijerph-15-01006]\].](ijerph-15-01006-g001){#ijerph-15-01006-f001}

![Comparison of the cancer incidence rate and average annual percent change (AAPC) between Taean and the whole of Korea, 1999−2014; Model selection and *p*-value estimated using the Monte Carlo Permutation method. (**A**) All cancers (C00−C96) excluding thyroid cancer (C73) in men; (**B**) All cancers (C00−C96) excluding thyroid cancer (C73) in women; (**C**) Prostate cancer (C61); and (**D**) Leukemia (C91−C95) in women. The Hebei Spirit oil spill (HSOS) occurred in 7 December 2007.](ijerph-15-01006-g002){#ijerph-15-01006-f002}

![Comparison of the cancer incidence rate and average annual percent change (AAPC) between Taean and the other coastal areas, 1999−2014; Model selection and *p*-value estimated using the Monte Carlo Permutation method. (**A**) All cancers (C00−C96) excluding thyroid cancer (C73) in men; (**B**) All cancers (C00−C96) excluding thyroid cancer (C73) in women; (**C**) Prostate cancer (C61); and (**D**) Leukemia (C91−C95) in women. Coastal areas were selected based on their similarities to Taean in terms of the characteristics and population size. This has been illustrated in [Figure 1](#ijerph-15-01006-f001){ref-type="fig"}. The Hebei Spirit oil spill (HSOS) occurred in 7 December 2007.](ijerph-15-01006-g003){#ijerph-15-01006-f003}
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###### 

Age-standardized incidence rate and incidence rate ratio of five major cancers and leukemia according to the Hebei Spirit oil spill exposure areas in Taean, Korea, 1999−2014.

  Cancer Type                                    Taean                                                                                                                              
  ---------------------------------------------- ------- ------- ---------------- ---------------- ----- ------- ----------------- ----------------- ----- ------- ---------------- ----------------
  **Male**                                                                                                                                                                          
  All cancer (C00−C96)                                                                                                                                                              
  1999−2003                                      753     318.0   1.1 (1.0, 1.2)   1.0 (0.9, 1.1)   284   309.7   1.1 (0.9, 1.2)    1.0 (0.9, 1.1)    420   288.8   1.0 (0.9, 1.1)   0.9 (0.8, 1.0)
  2004−2008                                      872     314.6   1.0 (0.9, 1.1)   0.9 (0.8, 1.0)   323   309.2   1.0 (0.9, 1.1)    0.9 (0.8, 1.0)    547   315.2   1.0 (0.9, 1.1)   0.9 (0.8, 1.0)
  2009−2014                                      1430    350.0   1.1 (1.0, 1.1)   1.0 (0.9, 1.1)   557   370.8   1.1 (1.0, 1.2)    1.1 (1.0, 1.2)    873   340.5   1.0 (1.0, 1.1)   1.0 (0.9, 1.1)
  All cancer (C00−C96) excluding thyroid (C73)                                                                                                                                      
  1999−2003                                      748     315.6   1.1 (1.0, 1.2)   1.0 (0.9, 1.1)   283   309.7   1.1 (0.9, 1.2)    1.0 (0.9, 1.1)    416   288.8   1.0 (0.9, 1.1)   0.9 (0.8, 1.0)
  2004−2008                                      845     302.5   1.0 (0.9, 1.1)   0.9 (0.8, 1.0)   315   309.2   1.0 (0.9, 1.1)    0.9 (0.8, 1.0)    528   315.2   1.0 (0.9, 1.1)   0.9 (0.8, 1.0)
  2009−2014                                      1369    325.3   1.1 (1.0, 1.1)   1.0 (0.9, 1.1)   531   370.8   1.1 (1.0, 1.2)    1.0 (0.9, 1.1)    838   340.5   1.0 (1.0, 1.1)   1.0 (0.9, 1.1)
  Stomach (C16)                                                                                                                                                                     
  1999−2003                                      207     89.6    1.3 (1.1, 1.6)   1.2 (1.0, 1.4)   69    81.4    1.2 (0.9, 1.6)    1.1 (0.8, 1.4)    123   85.2    1.3 (1.0, 1.5)   1.1 (0.9, 1.4)
  2004−2008                                      183     63.9    1.0 (0.8, 1.1)   0.9 (0.7, 1.0)   69    60.2    0.9 (0.7, 1.2)    0.8 (0.6, 1.1)    114   64.1    1.0 (0.8, 1.2)   0.9 (0.7, 1.1)
  2009−2014                                      277     67.1    1.1 (1.0, 1.3)   1.1 (0.9, 1.2)   101   64.4    1.1 (0.8, 1.3)    1.0 (0.8, 1.3)    176   67.5    1.1 (0.9, 1.3)   1.1 (0.9, 1.3)
  Lung (C33−C34)                                                                                                                                                                    
  1999−2003                                      128     51.2    1.0 (0.8, 1.2)   0.9 (0.7, 1.0)   58    55.1    1.1 (0.8, 1.4)    0.9 (0.7, 1.2)    60    40.3    0.8 (0.6, 1.0)   0.7 (0.5, 0.9)
  2004−2008                                      173     58.0    1.2 (1.0, 1.4)   1.0 (0.8, 1.2)   58    53.3    1.1 (0.8, 1.5)    0.9 (0.7, 1.2)    115   62.8    1.3 (1.0, 1.6)   1.1 (0.9, 1.3)
  2009−2014                                      257     53.2    1.2 (1.0, 1.3)   1.0 (0.9, 1.2)   102   56.3    1.2 (1.0, 1.6)    1.1 (0.9, 1.4)    155   53.1    1.2 (1.0, 1.4)   1.0 (0.9, 1.2)
  Colon (C18−C20)                                                                                                                                                                   
  1999−2003                                      55      22.7    0.7 (0.6, 0.9)   0.9 (0.6, 1.1)   22    21.3    0.7 (0.5, 1.0)    0.8 (0.5, 1.2)    32    21.7    0.7 (0.5, 0.9)   0.8 (0.6, 1.2)
  2004−2008                                      102     37.8    0.9 (0.7, 1.0)   1.1 (0.8, 1.3)   37    34.8    0.8 (0.6, 1.1)    1.0 (0.7, 1.4)    65    38.2    0.9 (0.7, 1.1)   1.1 (0.8, 1.4)
  2009−2014                                      197     48.7    1.0 (0.9, 1.2)   1.0 (0.9, 1.3)   69    50.2    1.0 (0.8, 1.4)    1.1 (0.8, 1.5)    128   49.0    1.0 (0.8, 1.2)   1.1 (0.9, 1.3)
  Liver (C22)                                                                                                                                                                       
  1999−2003                                      109     47.8    1.0 (0.9, 1.3)   0.9 (0.7, 1.1)   37    42.3    0.9 (0.7, 1.3)    0.8 (0.6, 1.1)    57    39.9    0.9 (0.7, 1.1)   0.8 (0.6, 1.0)
  2004−2008                                      114     43.6    1.0 (0.9, 1.3)   0.8 (0.7, 1.0)   40    43.0    1.0 (0.7, 1.5)    0.8 (0.6, 1.1)    74    43.8    1.0 (0.8, 1.3)   0.8 (0.7, 1.1)
  2009−2014                                      147     36.9    1.0 (0.9, 1.2)   0.8 (0.7, 1.0)   58    41.2    1.2 (0.8, 1.6)    0.9 (0.7, 1.2)    89    34.9    1.0 (0.8, 1.2)   0.8 (0.6, 0.9)
  Prostate (C61)                                                                                                                                                                    
  1999−2003                                      27      10.2    1.1 (0.7, 1.6)   1.3 (0.8, 2.1)   15    13.8    1.5 (0.8, 2.7)    1.8 (0.9, 3.6)    12    7.9     0.8 (0.5, 1.4)   1.0 (0.5, 1.9)
  2004−2008                                      36      12.2    0.7 (0.5, 0.9)   0.8 (0.6, 1.1)   14    12.3    0.7 (0.4, 1.0)    0.8 (0.5, 1.3)    22    11.8    0.6 (0.5, 0.9)   0.8 (0.5, 1.1)
  2009−2014                                      143     30.3    1.2 (1.0, 1.4)   1.2 (1.0, 1.5)   62    33.9    1.3 (1.0, 1.8)    1.4 (1.0, 1.9)    81    28.3    1.1 (0.9, 1.4)   1.2 (0.9, 1.5)
  Leukemia (C91−C95)                                                                                                                                                                
  1999−2003                                      14      6.6     1.3 (0.7, 2.3)   1.1 (0.6, 2.2)   5     6.6     1.3 (0.4, 3.8)    1.1 (0.4, 3.5)    9     6.6     1.2 (0.6, 2.6)   1.1 (0.5, 2.5)
  2004−2008                                      16      8.9     1.6 (0.8, 3.3)   1.3 (0.6, 2.5)   7     10.6    1.9 (0.5, 7.7)    1.5 (0.4, 5.2)    8     6.8     1.2 (0.6, 2.8)   1.0 (0.4, 2.1)
  2009−2014                                      14      4.7     0.8 (0.4, 1.5)   1.0 (0.5, 2.0)   4     2.2     0.4 (0.2, 0.7)    0.5 (0.2, 1.1)    10    5.6     1.0 (0.5, 2.0)   1.1 (0.5, 2.7)
  **Female**                                                                                                                                                                        
  All cancer (C00−C96)                                                                                                                                                              
  1999−2003                                      474     192.8   1.0 (0.9, 1.2)   1.1 (1.0, 1.3)   159   169.1   0.9 (0.8, 1.1)    1.0 (0.8, 1.2)    288   184.8   1.0 (0.9, 1.2)   1.1 (1.0, 1.3)
  2004−2008                                      679     264.4   1.1 (1.0, 1.2)   1.1 (1.0, 1.3)   233   251.2   1.1 (0.9, 1.3)    1.1 (0.9, 1.3)    446   266.9   1.1 (1.0, 1.2)   1.2 (1.0, 1.3)
  2009−2014                                      905     325.6   1.0 (1.0, 1.1)   1.1 (1.0, 1.2)   358   295.6   1.0 (0.8, 1.1)    1.0 (0.8, 1.2)    738   327.0   1.1 (1.0, 1.2)   1.1 (1.0, 1.2)
  All cancer (C00−C96) excluding thyroid (C73)                                                                                                                                      
  1999−2003                                      434     170.0   1.0 (0.9, 1.2)   1.2 (1.0, 1.3)   148   155.7   0.9 (0.8, 1.2)    1.1 (0.9, 1.3)    259   162.0   1.0 (0.9, 1.1)   1.1 (1.0, 1.3)
  2004−2008                                      527     185.4   1.0 (0.9, 1.1)   1.1 (1.0, 1.2)   188   184.6   1.0 (0.8, 1.2)    1.1 (0.9, 1.3)    338   186.7   1.0 (0.9, 1.1)   1.1 (0.9, 1.3)
  2009−2014                                      805     198.3   1.0 (0.9, 1.1)   1.1 (1.0, 1.2)   270   188.2   0.9 (0.8, 1.2)    1.0 (0.8, 1.3)    535   204.8   1.0 (0.9, 1.1)   1.1 (1.0, 1.3)
  Thyroid (C73)                                                                                                                                                                     
  1999−2003                                      40      20.2    1.2 (0.8, 1.7)   1.0 (0.7, 1.5)   11    13.3    0.8 (0.4, 1.4)    0.7 (0.4, 1.2)    29    22.7    1.4 (0.9, 2.1)   1.1 (0.7, 1.8)
  2004−2008                                      153     76.7    1.4 (1.1, 1.7)   1.3 (1.1, 1.7)   45    66.6    1.2 (0.8, 1.8)    1.2 (0.8, 1.8)    108   80.2    1.5 (1.1, 1.9)   1.4 (1.1, 1.8)
  2009−2014                                      291     119.3   1.1 (1.0, 1.3)   1.1 (0.9, 1.2)   88    107.4   1.0 (0.8, 1.4)    1.0 (0.7, 1.3)    203   122.2   1.2 (1.0, 1.4)   1.1 (0.9, 1.3)
  Breast (C50)                                                                                                                                                                      
  1999−2003                                      57      31.9    1.1 (0.8, 1.5)   1.8 (1.2, 2.6)   17    28.1    1.0 (0.6, 1.7)    1.5 (0.8, 3.1)    40    33.4    1.2 (0.8, 1.7)   1.8 (1.2, 2.9)
  2004−2008                                      75      39.3    1.0 (0.8, 1.3)   1.4 (1.0, 1.9)   25    42.1    1.1 (0.6, 1.9)    1.4 (0.8, 2.8)    50    38.7    1.0 (0.7, 1.3)   1.3 (0.9, 1.9)
  2009−2014                                      118     46.4    0.9 (0.8, 1.1)   1.4 (1.0, 1.8)   35    39.5    0.8 (0.5, 1.2)    1.2 (0.7, 1.9)    83    47.6    1.0 (0.8, 1.2)   1.4 (1.0, 1.9)
  Colon (C18−C20)                                                                                                                                                                   
  1999−2003                                      60      20.9    1.1 (0.8, 1.5)   1.3 (0.9, 1.9)   16    11.8    0.6 (0.4, 1.0)    0.7 (0.4, 1.2)    42    24.5    1.3 (0.9, 1.9)   1.5 (1.0, 2.3)
  2004−2008                                      66      21.0    0.9 (0.7, 1.1)   0.9 (0.6, 1.2)   22    19.9    0.8 (0.5, 1.4)    0.8 (0.5, 1.4)    44    21.8    0.9 (0.7, 1.2)   0.9 (0.6, 1.3)
  2009−2014                                      130     23.0    0.9 (0.7, 1.0)   0.9 (0.7, 1.2)   39    17.9    0.7 (0.5, 0.9)    0.7 (0.5, 1.0)    91    25.7    1.0 (0.8, 1.2)   1.0 (0.8, 1.4)
  Stomach (C16)                                                                                                                                                                     
  1999−2003                                      82      29.1    1.1 (0.8, 1.4)   1.1 (0.8, 1.4)   28    29.4    1.1 (0.6, 1.8)    1.1 (0.6, 1.9)    49    27.3    1.0 (0.7, 1.3)   1.0 (0.7, 1.4)
  2004−2008                                      96      31.3    1.2 (0.9, 1.5)   1.1 (0.8, 1.5)   32    25.3    0.9 (0.6, 1.6)    0.9 (0.5, 1.5)    64    34.0    1.3 (0.9, 1.7)   1.2 (0.9, 1.7)
  2009−2014                                      139     31.6    1.2 (1.0, 1.6)   1.1 (0.9, 1.5)   46    26.8    1.1 (0.6, 1.7)    1.0 (0.6, 1.6)    93    33.4    1.3 (1.0, 1.8)   1.2 (0.9, 1.6)
  Lung (C33−C34)                                                                                                                                                                    
  1999−2003                                      46      14.5    1.2 (0.8, 1.6)   1.1 (0.8, 1.7)   19    11.8    0.9 (0.6, 1.5)    0.9 (0.6, 1.5)    22    12.7    1.0 (0.6, 1.6)   1.0 (0.6, 1.6)
  2004−2008                                      60      15.4    1.1 (0.8, 1.5)   1.4 (1.0, 2.1)   18    11.9    0.9 (0.5, 1.4)    1.1 (0.6, 2.0)    42    18.0    1.3 (0.9, 1.9)   1.7 (1.1, 2.6)
  2009−2014                                      90      15.3    1.0 (0.8, 1.3)   1.2 (0.8, 1.6)   37    19.8    1.3 (0.7, 2.6)    1.5 (0.7, 3.1)    53    14.3    1.0 (0.7, 1.3)   1.1 (0.8, 1.5)
  Leukemia (C91−C95)                                                                                                                                                                
  1999−2003                                      11      5.1     1.3 (0.6, 2.8)   1.5 (0.6, 3.7)   2     1.4     0.4 (0.2, 0.8)    0.4 (0.1, 1.2)    7     5.0     1.3 (0.5, 3.2)   1.5 (0.5, 4.2)
  2004−2008                                      13      5.7     1.4 (0.6, 3.1)   1.1 (0.5, 2.5)   6     10.8    2.7 (0.5, 15.2)   2.1 (0.4, 10.3)   7     3.9     1.0 (0.4, 2.2)   0.8 (0.3, 1.9)
  2009−2014                                      13      7.3     1.8 (0.7, 4.5)   1.9 (0.7, 5.0)   6     20.8    5.1 (0.7, 36.3)   5.3 (0.7, 39.1)   7     4.2     1.0 (0.4, 2.8)   1.1 (0.3, 3.3)

^1^ The number of cases in Taean may vary in terms of the sum of the high-exposure and low-exposure areas, in situations in which address details were absent; ^2^ Standardized incidence rate: Rate per 100,000; The standard population was the Korean mid-year population in 2000; ^3^ The standardized incidence rate ratio was calculated as the standardized incidence rate in Taean divided by that in Korea and the 95% CI was estimated using the standardized incidence rate and the formula proposed by Boyle P. and Parkin D.M ("Statistical methods for registries" from book of "Cancer Registration: Principles and Methods" (IARC Scientific Publications No. 95)); ^4^ The standardized incidence rate ratio was calculated as the standardized incidence rate in Taean divided by that in the coastal area and the 95% CI was estimated using the standardized incidence rate and the above-stated formula. The coastal areas were selected based on their similarities to Taean, in terms of their characteristics and population size. This has been illustrated in [Figure 1](#ijerph-15-01006-f001){ref-type="fig"}. CI, confidence interval; SIR, standardized incidence rate; IRR, incidence rate ratio.
